Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

Common genetic variants linked to schizophrenia and bipolar disorder

Knowledge about the biological origin of diseases like schizophrenia, bipolar disorder and other psychiatric conditions is critical to improving diagnosis and treatment.

22 Sep 2011

Common DNA variations contribute to schizophrenia, bipolar disorder

A team of over 250 researchers from more than 20 countries have discovered that common genetic variations contribute to a person's risk of schizophrenia and bipolar disorder.

20 Sep 2011

Scientists discover common genetic variants associated with schizophrenia and bipolar disorder

Common genetic variants contribute to the risk of schizophrenia and bipolar disorder, an international research consortium has discovered.

19 Sep 2011

Landmark international study confirms common genetic contribution to mental illness

An international research consortium has confirmed that common genetic variants contribute to a person’s risk of schizophrenia and bipolar disorder. The largest study of its kind provides new molecular evidence that 11 regions have strong association with these diseases, including six regions not previously observed. The researchers also found that many of these DNA variations contribute to both diseases. The findings, reported by the Psychiatric Genome-Wide Association Study Consortium (PGC) and published online in two papers in the journal Nature Genetics, represent significant advances in the understanding the causes of these severe and often debilitating disorders.

18 Sep 2011

New report finds improvements in hospital performance

Meanwhile, Reuters reports on the quality of weekend care at stroke centers and nursing homes are trying to reduce their use of powerful antipsychotic drugs for patients with dementia.

16 Sep 2011

First Edition: September 15, 2011

In today's news, reports about what might be included in President Obama's detailed plan to tame the federal federal budget. Here's a hint: Social Security changes are unlikely, but what about Medicare?

15 Sep 2011

UB transgenic mouse model of Timothy Syndrome improves understanding of autism

The first transgenic mouse model of a rare and severe type of autism called Timothy Syndrome is improving the scientific understanding of autism spectrum disorder in general and may help researchers design more targeted interventions and treatments.

12 Sep 2011

Lundbeck Canada makes landmark donation of $2.7M to support depression research

Lundbeck Canada has made a landmark donation of $2.7 million to support ground-breaking research at the University Health Network to identify biomarkers that will enhance the diagnosis and treatment of patients suffering from major depression and bipolar disorder.

29 Aug 2011

Nurofen mix up with Seroquel schizophrenia drug warns MHRA

British drug regulators have issued a safety alert on Thursday after discovering packs of the over-the-counter painkiller Nurofen Plus containing the anti-psychotic drug Seroquel XL.

26 Aug 2011

Study reveals striking brain similarities in bipolar disorder and schizophrenia

Researchers from the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital have conducted a study which has found striking brain similarities in bipolar disorder and schizophrenia. The research has also pinpointed for the first time that a process which controls how information is transmitted from neuron to neuron in the brain is altered in both conditions and may potentially contribute to the developments of improved treatments in the future.

25 Aug 2011

KFDA approves IND for DP-b99 Phase III MACSI stroke study in Korea

D-Pharm Ltd., announced today that the Korean Food & Drug Administration (KFDA) approved the Investigational New Drug application for the Phase III MACSI study of DP-b99 in Korea. The IND has been submitted by D-Pharm's co-development partner in South Korea, Yungjin Pharmaceutical Company Ltd..

24 Aug 2011

People admitted to hospital for mental illness more likely to experience control intervention

The use of control interventions, including physical and mechanical restraints, acute control medications and seclusion, is intended to be a method of last resort in Ontario care facilities, including hospitals.

24 Aug 2011

Children of women with HG more likely to suffer from anxiety, bipolar disorder

An extreme form of pregnancy-related nausea and vomiting known as hyperemesis gravidarum (HG) takes a heavy toll on thousands of women each year and can lead to hospitalization and pregnancy termination. But new research suggests pregnant women are not the only victims.

24 Aug 2011

New stem cell lines help study genetic, biological underpinnings of bipolar disorder

New stem cell lines developed from the skin of adults living with bipolar disorder are providing researchers at the University of Michigan Health System an unprecedented opportunity to delve into the genetic and biological underpinnings of the devastating mood disorder.

24 Aug 2011

FDA accepts Alexza ADASUVE NDA, assigns PDUFA action date

Alexza Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration (FDA) has accepted the ADASUVE New Drug Application (NDA) as a complete, class 2 response to the FDA's action letter, with an indicated Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.

20 Aug 2011

First Edition: August 18, 2011

"The SSI program for children is rapidly expanding, with the biggest increase among kids with mental, behavioral and learning disorders, including ADHD, speech delays, autism, and bipolar disorder. But as it pulls in children like Hulston, the program is sparking criticism in Congress.

18 Aug 2011

Study finds decrease in inpatient hospitalizations for the elderly with psychiatric diagnosis

Short-stay inpatient hospitalizations for children and adolescents with a psychiatric diagnosis increased significantly over a 12-year period (1996 to 2007) and decreased for the elderly, according to a report in the early online edition in Archives of General Psychiatry by Joseph C. Blader, Ph.D., Assistant Professor, Department of Psychiatry & Behavioral Science at Stony Brook University School of Medicine.

12 Aug 2011

Alexza resubmits AZ-004 NDA for treatment of agitation in schizophrenia patients

Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.

5 Aug 2011

RACGP urging the government to restore mental health rebates

In its submission to the Senate Standing Committee on Community Affairs regarding the Commonwealth funding and administration of mental health services, the Royal Australian College of General Practitioners (RACGP) strongly argued for the restoration of GP mental health services. The College is gravely concerned regarding the proposed cuts to the Better Access program and the subsequent impact on mental health delivery for every patient age group, demographic and geography throughout Australia.

3 Aug 2011

Risperidone does not appear to reduce military-related PTSD symptoms

Patients with military-related, chronic posttraumatic stress disorder (PTSD) and symptoms that were not improved with use of an antidepressant medication did not experience a reduction in PTSD symptoms with use of the antipsychotic medication risperidone, according to a study in the August 3 issue of JAMA, a theme issue on violence and human rights.

3 Aug 2011